The Rising Influence of Rising Affluence

[DewDiligence]

ABT addendum: It’s been 2.5 years since the ABT/ABBV separation and it’s only now that the business of selling branded generics is really beginning to shine. ABT owes a big “thank you” to MYL for buying ABT’s moribund branded-generics business in Europe and other developed markets (in order to do a tax inversion into a Dutch–based company).

Any of the Big Pharma could have done what ABT is doing, but only ABT had the foresight to see that selling branded generics in emerging markets would be not just a decent business, but rather a superb business with a longrunning demographic tailwind.